Precision Path to Effective Immunotherapy - Tumor Mutational Burden (TMB) Assessment

This genetic test quantifies the number of mutations within tumor DNA. It serves as a vital biomarker to identify patients likely to benefit from immune checkpoint inhibitors, optimizing oncology treatment precision.